Assesses risk of prostate cancer. For men of European descent it detects 27 genetic markers with the results ranging from 0.2 to 5-fold the general population risk. 6% will have results that more than doubles their risk, which is of the same frequency and impact as having one first degree relative with the disease. For men of African ancestry the test detects 9 markers, identifying the 12% who have 1.5 to 3-fold risk. For East Asian ancestry the test analyses 12 markers identifying the 7% with risk in the range of 2 to 8-fold the general risk.
A risk test for the common form of breast cancer. In women of European descent the test looks at 16 genetic markers. The results fall within a range of 0.4 to 7.5-fold the average population
risk. 6% of women of European descent will have a relative risk >1.65, corresponding to >20% lifetime risk. The American Cancer Society recommends MRI for those with a lifetime risk > 20%. For women of East Asian descent the test analyzes five markers with results ranging within 0.5 and 2.6 fold the general East Asian population risk. This test has not yet been validated for women of other ethnicities.
Gauges risk of atrial fibrillation, identifying stroke patients for whom ambulatory Holter monitoring may be indicated. For individuals of European descent, results range from 0.52- to 5.46-fold average population risk. About 7% will have relative risk of 1.5 or higher and about 2% over 2.0. The test identifies the 30% of people of East Asian descent who are at 1.33-fold the population average risk of getting AF. Not yet applicable to other ethnicities.
A test for risk of exfoliation glaucoma. The test looks for homozygosity of two markers in the LOXL1 gene on chromosome 15. Twenty-eight percent of those of European descent test positive and have 2.5-fold the population average risk. XFG accounts for 10-30% of open-angle glaucoma. The test is as yet only validated in people of European descent.
A test for risk of developing type 2 diabetes (T2D). Measures 21 markers in individuals of European descent, 9 in people of East Asian descent and 2 in those of African descent; with risk ranges of 0.05-12.0, 0.17-16.2 and 0.6-20.3-fold average population risk, respectively. Of these populations, 3%, 5% and 2.6 %, respectively, will have >2-fold relative risk. The test also predicts risk of conversion from pre- to full-blown diabetes, as well as diabetes drug response.
Assesses risk of myocardial infarction (MI, or heart attack). For those of European descent it analyzes eight markers, with results ranging from 0.5- to 2.0-fold population-average risk, with 5.5 % having relative risk >1.5. This is independent of conventional risk factors and can be used to multiply the Framingham risk score for a more complete risk assessment. For those of East Asian origin, it detects two markers identifying the 23% of the population that has 1.4- to 1.95-fold population average risk. It is not yet validated in other ethnicities.
A DNA based CYP2C19 test that looks for 5 alleles (*2, *3, *4, *8, *17) known to change the efficiency of the hepatic P450 2C19 enzyme to convert the pro-drug clopidogrel to its active metabolite. The test detects the 1-23% of the population that have altered anti-platelet response to prophylactic clopidogrel treatment and thereby possibly increased risk for recurrent adverse cardiovascular events.The FDA has added a Boxed Warning to the label for clopidogrel, informing health care providers of the CYP2C19 genetic test for the identification “poor metabolizers”.
A cost-effective choice for the health-conscious. Analyzes risk for 50 diseases and various traits. deCODE Complete is not customarily reimbursable.
A single test that measures risk for multiple common cancers: colon, lung, bladder, thyroid and basal cell carcinoma, as well as breast and ovarian in women and prostate and testicular cancer in men.
Assesses, in one test, risk of eight diseases: myocardial infarction, type 2 diabetes, atrial fibrillation, abdominal aortic aneurysm, intra cranial aneurysm and venous thromboembolism, as well as clopidogrel metabolizing status.
This content was last reviewed on June 15, 2011.